TY  - JOUR
AU  - Scuteri, Damiana
AU  - Tonin, Paolo
AU  - Nicotera, Pierluigi
AU  - Vulnera, Marilù
AU  - Altieri, Giuseppina Cristina
AU  - Tarsitano, Assunta
AU  - Bagetta, Giacinto
AU  - Corasaniti, Maria Tiziana
TI  - Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine.
JO  - Toxins
VL  - 14
IS  - 8
SN  - 2072-6651
CY  - Basel
PB  - MDPI
M1  - DZNE-2022-01439
SP  - 529
PY  - 2022
N1  - CC BY: https://creativecommons.org/licenses/by/4.0/
AB  - OnabotulinumtoxinA, targeting the CGRP machinery, has been approved for the last two decades for chronic migraine prevention. The recently approved monoclonal antibodies (mAbs) directed towards the calcitonin gene-related peptide (CGRP) pathway open a new age for chronic migraine control. However, some 40
KW  - Antibodies, Monoclonal: therapeutic use
KW  - Botulinum Toxins, Type A: therapeutic use
KW  - Calcitonin Gene-Related Peptide: antagonists & inhibitors
KW  - Drug Therapy, Combination: adverse effects
KW  - Humans
KW  - Migraine Disorders: prevention & control
KW  - Treatment Outcome
KW  - PRISMA 2020 (Other)
KW  - anti-CGRP monoclonal antibodies (Other)
KW  - migraine (Other)
KW  - onabotulinumtoxinA (Other)
KW  - pooled analysis (Other)
KW  - Antibodies, Monoclonal (NLM Chemicals)
KW  - Botulinum Toxins, Type A (NLM Chemicals)
KW  - Calcitonin Gene-Related Peptide (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:36006191
C2  - pmc:PMC9413678
DO  - DOI:10.3390/toxins14080529
UR  - https://pub.dzne.de/record/165134
ER  -